600867 通化东宝
交易中 12-16 14:56:19
资讯
新帖
简况
通化东宝（600867）披露研发生产系统员工持股计划草案，12月4日股价下跌0.68%
证券之星 · 12-04
通化东宝（600867）披露研发生产系统员工持股计划草案，12月4日股价下跌0.68%
通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，12月02日股价下跌0.23%
证券之星 · 12-02
通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，12月02日股价下跌0.23%
通化东宝(600867.SH)拟推研发生产系统员工持股计划
智通财经 · 11-28
通化东宝(600867.SH)拟推研发生产系统员工持股计划
通化东宝(600867.SH)：门冬胰岛素注射液获得境外药品注册证书
智通财经 · 11-12
通化东宝(600867.SH)：门冬胰岛素注射液获得境外药品注册证书
每周股票复盘：通化东宝（600867）完成董监高调整及首次股份回购
证券之星 · 11-09
每周股票复盘：通化东宝（600867）完成董监高调整及首次股份回购
通化东宝（600867）披露关于取消监事会并修订《公司章程》的议案，11月03日股价上涨2.66%
证券之星 · 11-03
通化东宝（600867）披露关于取消监事会并修订《公司章程》的议案，11月03日股价上涨2.66%
每周股票复盘：通化东宝（600867）控股股东完成增持1.42%股份
证券之星 · 11-02
每周股票复盘：通化东宝（600867）控股股东完成增持1.42%股份
通化东宝（600867）披露控股股东增持公司股份结果公告，10月31日股价上涨2.61%
证券之星 · 10-31
通化东宝（600867）披露控股股东增持公司股份结果公告，10月31日股价上涨2.61%
10月30日通化东宝发布公告，股东增持567.73万股
证券之星 · 10-30
10月30日通化东宝发布公告，股东增持567.73万股
通化东宝（600867）2025年三季报简析：营收净利润同比双双增长
证券之星 · 10-29
通化东宝（600867）2025年三季报简析：营收净利润同比双双增长
股市必读：通化东宝(600867)股东户数8.21万户，较上期减少5.08%
证券之星 · 10-29
股市必读：通化东宝(600867)股东户数8.21万户，较上期减少5.08%
通化东宝（600867）披露计提资产减值准备和核销资产公告，10月27日股价上涨0.79%
证券之星 · 10-27
通化东宝（600867）披露计提资产减值准备和核销资产公告，10月27日股价上涨0.79%
通化东宝最新公告：第三季度净利润同比增长499.86%
证券之星 · 10-27
通化东宝最新公告：第三季度净利润同比增长499.86%
每周股票复盘：通化东宝（600867）拟回购股份并取消监事会
证券之星 · 10-26
每周股票复盘：通化东宝（600867）拟回购股份并取消监事会
通化东宝（600867）披露拟取消监事会并变更会计师事务所，10月24日股价上涨1.14%
证券之星 · 10-24
通化东宝（600867）披露拟取消监事会并变更会计师事务所，10月24日股价上涨1.14%
通化东宝(600867.SH)：门冬胰岛素注射液获得境外药品注册证书
智通财经 · 10-24
通化东宝(600867.SH)：门冬胰岛素注射液获得境外药品注册证书
通化东宝（600867）披露回购股份事项前十大股东持股情况，10月22日股价下跌0.68%
证券之星 · 10-22
通化东宝（600867）披露回购股份事项前十大股东持股情况，10月22日股价下跌0.68%
每周股票复盘：通化东宝（600867）拟回购2000万至4000万元股份
证券之星 · 10-19
每周股票复盘：通化东宝（600867）拟回购2000万至4000万元股份
通化东宝（600867）披露拟取消监事会并修订公司章程公告，10月17日股价下跌1.46%
证券之星 · 10-17
通化东宝（600867）披露拟取消监事会并修订公司章程公告，10月17日股价下跌1.46%
通化东宝(600867.SH)拟2000万元至4000万元回购公司股份
智通财经 · 10-17
通化东宝(600867.SH)拟2000万元至4000万元回购公司股份
加载更多
公司概况
公司名称：
通化东宝药业股份有限公司
所属行业：
医药制造业
上市日期：
1994-08-24
主营业务：
通化东宝药业股份有限公司的主营业务是糖尿病及内分泌治疗领域生物制品、中成药、化学药等药品的研发、生产和销售。公司的主要产品是人胰岛素原料药、人胰岛素注射剂（注册商标：甘舒霖）、甘精胰岛素原料药、甘精胰岛素注射液（注册商标：平舒霖）、门冬胰岛素原料药、门冬胰岛素注射液、预混型门冬胰岛素（门冬胰岛素30注射液与门冬胰岛素50注射液）（注册商标：锐舒霖）、利拉鲁肽注射液（注册商标：统博力）、恩格列净片（注册商标：唐捷恩）、镇脑宁胶囊、糖尿病。公司被国家认定为高新技术企业、国家技术创新示范企业。
发行价格：
6.50
{"stockData":{"symbol":"600867","market":"SH","secType":"STK","nameCN":"通化东宝","latestPrice":8.43,"timestamp":1765868179000,"preClose":8.63,"halted":0,"volume":24354798,"delay":0,"changeRate":-0.0232,"floatShares":1959000000,"shares":1959000000,"eps":0.626,"marketStatus":"交易中","change":-0.2,"latestTime":"12-16 14:56:19","open":8.61,"high":8.65,"low":8.4,"amount":206000000,"amplitude":0.029,"askPrice":8.43,"askSize":2,"bidPrice":8.42,"bidSize":740,"shortable":0,"etf":0,"ttmEps":0.626,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765868400000},"marketStatusCode":2,"adr":0,"adjPreClose":8.63,"symbolType":"stock","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":9.49,"lowLimit":7.77,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1958542829,"isCdr":false,"pbRate":2.37,"roa":"--","peRate":13.466454,"roe":"17.77%","epsLYR":-0.02,"committee":0.358199,"marketValue":16511000000,"turnoverRate":0.0124,"status":1,"floatMarketCap":16511000000},"requestUrl":"/m/hq/s/600867","defaultTab":"news","newsList":[{"id":"2588880812","title":"通化东宝（600867）披露研发生产系统员工持股计划草案，12月4日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880812?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:11","pubTimestamp":1764857479,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，通化东宝报收于8.76元，较前一交易日下跌0.68%，最新总市值为171.57亿元。公司近日发布公告，披露将召开2025年第四次临时股东会，审议《研发生产系统员工持股计划（草案）》及其摘要、《员工持股计划管理办法》等相关议案。根据公告内容，本次员工持股计划的参与对象为公司研发生产系统的核心骨干人员，首次授予人数不超过122人，拟持有标的股票总数为700万股，占公司总股本的0.357%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600867","BK0239","BK0196"],"gpt_icon":0},{"id":"2588059576","title":"通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，12月02日股价下跌0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059576","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588059576?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:13","pubTimestamp":1764684789,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，通化东宝报收于8.74元，较前一交易日下跌0.23%，最新总市值为171.18亿元。公司近日发布公告称，通化东宝药业股份有限公司于2025年10月17日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购资金总额不低于2,000万元且不超过4,000万元，回购价格不超过10元/股，回购期限为2025年10月17日至2026年4月16日，回购股份拟用于员工持股计划或股权激励。上述回购进展符合相关规定及公司回购方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0188","BK0239","BK0196"],"gpt_icon":0},{"id":"2586853785","title":"通化东宝(600867.SH)拟推研发生产系统员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2586853785","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586853785?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:17","pubTimestamp":1764325029,"startTime":"0","endTime":"0","summary":"智通财经APP讯，通化东宝 披露研发生产系统员工持股计划(草案)，参与总人数不超过122人，员工持股计划拟筹集资金总额上限为3073万元，以“份”作为认购单位，每份份额为1元。员工持股计划拟受让的股票总数合计不超过700万股，占公司当前股本总额的0.357%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0188","600867","BK0239"],"gpt_icon":0},{"id":"2582328911","title":"通化东宝(600867.SH)：门冬胰岛素注射液获得境外药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582328911","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582328911?lang=zh_cn&edition=full","pubTime":"2025-11-12 15:48","pubTimestamp":1762933701,"startTime":"0","endTime":"0","summary":"智通财经APP讯，通化东宝(600867.SH)发布公告，公司于近日收到多米尼加共和国公共卫生和社会福利部签发的门冬胰岛素注射液的药品注册证书(注册证号：RM2025-1863)。门冬胰岛素注射液是一种速效胰岛素类似物，皮下注射后10-20分钟起效，作用持续时间3-5个小时，主要控制餐后血糖。门冬胰岛素通常在餐前即刻给药，必要时也可在餐后立即给药。门冬胰岛素具有起效快，作用持续时间较短，通常与长效胰岛素联合使用以实现患者的基础与餐后血糖控制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600867","BK0239","BK0196","BK0188"],"gpt_icon":0},{"id":"2582725861","title":"每周股票复盘：通化东宝（600867）完成董监高调整及首次股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2582725861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582725861?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:30","pubTimestamp":1762633831,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，通化东宝报收于9.14元，较上周的9.03元上涨1.22%。本周，通化东宝11月4日盘中最高价报9.67元，股价触及近一年最高点。公司公告汇总吉林秉责律师事务所就通化东宝2025年第三次临时股东会出具法律意见书。出席会议股东共599人，代表股份881,399,412股，占公司总股本的45.0028%。截至公告日，持有公司股份264,120股，占总股本0.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600867","BK0196"],"gpt_icon":0},{"id":"2580214516","title":"通化东宝（600867）披露关于取消监事会并修订《公司章程》的议案，11月03日股价上涨2.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580214516","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580214516?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:35","pubTimestamp":1762180524,"startTime":"0","endTime":"0","summary":"根据公司近日发布的公告，通化东宝药业股份有限公司于2025年11月3日召开2025年第三次临时股东会，会议审议通过了《关于取消监事会并修订<公司章程>的议案》、《关于修订和新增公司部分治理制度的议案》及《关于变更会计师事务所的议案》。其中，《关于取消监事会并修订<公司章程>的议案》作为特别决议事项，已获得出席股东所持表决权的2/3以上同意。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300036269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0239","BK0188","BK0196"],"gpt_icon":0},{"id":"2580547732","title":"每周股票复盘：通化东宝（600867）控股股东完成增持1.42%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2580547732","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580547732?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:15","pubTimestamp":1762038916,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，通化东宝报收于9.03元，较上周的8.9元上涨1.46%。本周关注点股本股东变化：控股股东东宝集团完成增持1.42%股份，合计持股比例达32.75%。股本股东变化股东增减持10月30日通化东宝发布公告，股东东宝实业集团股份有限公司于2025年10月18日至10月30日期间合计增持567.73万股，占公司总股本的0.2899%，期间股价持平，截至10月30日收盘价为8.8元。截至2025年10月30日，东宝集团已完成增持2,780.1409万股，占公司总股本1.42%，增持金额22,800.59万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600867","BK0196"],"gpt_icon":0},{"id":"2579452600","title":"通化东宝（600867）披露控股股东增持公司股份结果公告，10月31日股价上涨2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579452600","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579452600?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:07","pubTimestamp":1761905265,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，通化东宝报收于9.03元，较前一交易日上涨2.61%，最新总市值为176.86亿元。近日，通化东宝发布关于控股股东增持公司股份结果的公告。截至2025年10月30日，东宝集团实际增持27,801,409股，占公司当前总股本的1.42%，增持金额22,800.59万元，已超过增持计划下限，本次增持计划实施完毕。增持后，东宝集团及其一致行动人合计持股比例由31.06%增至32.75%。本次增持未导致公司控股股东及实际控制人变化，不影响公司上市条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100039090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0188","BK0196","BK0239"],"gpt_icon":0},{"id":"2579116631","title":"10月30日通化东宝发布公告，股东增持567.73万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2579116631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579116631?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:01","pubTimestamp":1761818479,"startTime":"0","endTime":"0","summary":"证券之星消息，10月30日通化东宝发布公告《通化东宝:通化东宝关于控股股东增持公司股份结果公告》，其股东东宝实业集团股份有限公司于2025年10月18日至2025年10月30日间合计增持567.73万股，占公司目前总股本的0.2899%，变动期间该股股价上涨0.0%，截止10月30日收盘报8.8元。股东增减持详情见下表：根据通化东宝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000035566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0196","BK0188","BK0239"],"gpt_icon":0},{"id":"2579913763","title":"通化东宝（600867）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2579913763","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579913763?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:07","pubTimestamp":1761689265,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期通化东宝发布2025年三季报。根据财报显示，通化东宝营收净利润同比双双增长。截至本报告期末，公司营业总收入21.8亿元，同比上升50.55%，归母净利润12.02亿元，同比上升1911.35%。按单季度数据看，第三季度营业总收入8.06亿元，同比上升13.9%，第三季度归母净利润9.84亿元，同比上升499.86%。持有通化东宝最多的基金为中加中证500指数增强A，目前规模为0.14亿元，最新净值1.2581，较上一交易日上涨1.59%，近一年上涨32.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900008463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867"],"gpt_icon":0},{"id":"2579967664","title":"股市必读：通化东宝(600867)股东户数8.21万户，较上期减少5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579967664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579967664?lang=zh_cn&edition=full","pubTime":"2025-10-29 00:52","pubTimestamp":1761670332,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，通化东宝报收于8.9元，下跌0.78%，换手率3.96%，成交量77.48万手，成交额6.82亿元。交易信息汇总资金流向10月28日主力资金净流出1.01亿元，占总成交额14.82%；游资资金净流入1.02亿元，占总成交额14.99%；散户资金净流出115.2万元，占总成交额0.17%。股本股东变化股东户数变动截至2025年9月30日，通化东宝股东户数为8.21万户，较6月30日减少4393户，减幅5.08%；户均持股数量由2.26万股增至2.38万股，户均持股市值为19.77万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900001868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","600867"],"gpt_icon":0},{"id":"2578647026","title":"通化东宝（600867）披露计提资产减值准备和核销资产公告，10月27日股价上涨0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578647026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578647026?lang=zh_cn&edition=full","pubTime":"2025-10-27 22:18","pubTimestamp":1761574713,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘，通化东宝报收于8.97元，较前一交易日上涨0.79%，最新总市值为175.68亿元。公司近日发布公告称，通化东宝药业股份有限公司于2025年10月27日以通讯方式召开第十一届董事会第十九次会议，审议通过《关于计提资产减值准备和核销资产的议案》。根据公告，公司依据《企业会计准则》等规定，结合实际情况，对截至2025年9月30日的相关资产进行减值测试，并据此计提资产减值准备及核销部分资产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700036269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0188","600867"],"gpt_icon":0},{"id":"2578611965","title":"通化东宝最新公告：第三季度净利润同比增长499.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578611965","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578611965?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:51","pubTimestamp":1761558712,"startTime":"0","endTime":"0","summary":"通化东宝(600867.SH)发布2025年第三季度报告，前三季度实现营业收入21.80亿元，同比增长50.55%；归属于上市公司股东的净利润12.02亿元。第三季度实现营业收入8.06亿元，同比增长13.90%；归属于上市公司股东的净利润9.84亿元，同比增长499.86%。业绩大幅增长主要系报告期内胰岛素类似物产品销量显著增长带动国内销售收入上升，同时海外业务多点突破推动出口收入增加，叠加转让特宝生物股票产生大额收益所致。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700025858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867"],"gpt_icon":0},{"id":"2578504430","title":"每周股票复盘：通化东宝（600867）拟回购股份并取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2578504430","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578504430?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:39","pubTimestamp":1761417550,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，通化东宝报收于8.9元，较上周的8.8元上涨1.14%。本周，通化东宝10月24日盘中最高价报8.93元。本周关注点公司公告汇总：通化东宝拟以集中竞价方式回购股份，前十大股东持股情况已披露。通化东宝2025年第三次临时股东会会议资料通化东宝药业股份有限公司拟召开2025年第三次临时股东会，审议三项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0188","BK0239","BK0196"],"gpt_icon":0},{"id":"2577517149","title":"通化东宝（600867）披露拟取消监事会并变更会计师事务所，10月24日股价上涨1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577517149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577517149?lang=zh_cn&edition=full","pubTime":"2025-10-24 22:15","pubTimestamp":1761315306,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，通化东宝报收于8.9元，较前一交易日上涨1.14%，最新总市值为174.31亿元。近日，通化东宝发布2025年第三次临时股东会会议资料，宣布将提交多项议案供股东审议。其中，拟取消公司监事会，并修订《公司章程》，由董事会审计委员会行使监事会职权，同时废止监事会相关制度。公司表示已与原审计机构北京德皓国际会计师事务所进行充分沟通，对方对变更事项无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400042632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0188","600867"],"gpt_icon":0},{"id":"2577882598","title":"通化东宝(600867.SH)：门冬胰岛素注射液获得境外药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2577882598","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577882598?lang=zh_cn&edition=full","pubTime":"2025-10-24 15:42","pubTimestamp":1761291777,"startTime":"0","endTime":"0","summary":"智通财经APP讯，通化东宝 发布公告，公司于近日收到印度尼西亚共和国食品药品监督管理局核准签发的门冬胰岛素注射液的药品注册证书。本次门冬胰岛素注射液获得印度尼西亚共和国食品药品监督管理局下发的药品注册证书，表明通化东宝具备向印度尼西亚销售门冬胰岛素注射液的许可，有利于丰富公司国际市场产品线，提升品牌形象，拓展国际业务，助力加速新兴市场布局，提高公司国际市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"通化东宝(600867.SH)：门冬胰岛素注射液获得境外药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600867","BK0239","BK0196"],"gpt_icon":0},{"id":"2577395508","title":"通化东宝（600867）披露回购股份事项前十大股东持股情况，10月22日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577395508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577395508?lang=zh_cn&edition=full","pubTime":"2025-10-22 22:30","pubTimestamp":1761143435,"startTime":"0","endTime":"0","summary":"截至2025年10月22日收盘，通化东宝报收于8.79元，较前一交易日下跌0.68%，最新总市值为172.16亿元。该股当日开盘8.81元，最高8.9元，最低8.77元，成交额达1.12亿元，换手率为0.65%。公司近日发布公告，披露了关于回购股份事项前十大股东及前十大无限售条件股东的持股情况。相关公告已于2025年10月18日披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200037666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0239","600867"],"gpt_icon":0},{"id":"2576049261","title":"每周股票复盘：通化东宝（600867）拟回购2000万至4000万元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2576049261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576049261?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:50","pubTimestamp":1760817020,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，通化东宝报收于8.8元，较上周的8.55元上涨2.92%。本周，通化东宝10月15日盘中最高价报9.04元。本周关注点公司公告汇总：通化东宝拟以2000万元至4000万元回购股份，用于员工持股计划或股权激励。公司公告汇总：通化东宝拟聘任大信会计师事务所为2025年度审计机构，审计费用150万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0188","BK0239","BK0196"],"gpt_icon":0},{"id":"2576801310","title":"通化东宝（600867）披露拟取消监事会并修订公司章程公告，10月17日股价下跌1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576801310","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576801310?lang=zh_cn&edition=full","pubTime":"2025-10-17 17:12","pubTimestamp":1760692325,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，通化东宝报收于8.8元，较前一交易日下跌1.46%，最新总市值为172.35亿元。近日，通化东宝发布关于召开2025年第三次临时股东会的通知。本次股东会审议事项包括《关于取消监事会并修订<公司章程>的议案》、《关于修订和新增公司部分治理制度的议案》及其子议案、《关于变更会计师事务所的议案》。其中，《关于变更会计师事务所的议案》将对中小投资者单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700027053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","600867","BK0188"],"gpt_icon":0},{"id":"2576082775","title":"通化东宝(600867.SH)拟2000万元至4000万元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2576082775","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576082775?lang=zh_cn&edition=full","pubTime":"2025-10-17 16:40","pubTimestamp":1760690434,"startTime":"0","endTime":"0","summary":"智通财经APP讯，通化东宝(600867.SH)发布公告，公司决定以自有资金回购公司股份用于员工持股计划及/或股权激励。此次回购股份金额不低于人民币2,000万元(含)，不超过人民币4,000万元(含)，回购股份价格不超过人民币10元/股(含)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600867","BK0239","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765868183289,"stockEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.063},{"period":"3month","weight":0.0385},{"period":"6month","weight":0.1516},{"period":"1year","weight":0.0585},{"period":"ytd","weight":0.1058}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.0307},{"period":"3month","weight":0.0016},{"period":"6month","weight":0.1414},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.154}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"通化东宝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"82143人(较上一季度减少5.08%)","perCapita":"23843股","listingDate":"1994-08-24","address":"吉林省通化市通化县东宝新村","registeredCapital":"195854万元","survey":" 通化东宝药业股份有限公司的主营业务是糖尿病及内分泌治疗领域生物制品、中成药、化学药等药品的研发、生产和销售。公司的主要产品是人胰岛素原料药、人胰岛素注射剂（注册商标：甘舒霖）、甘精胰岛素原料药、甘精胰岛素注射液（注册商标：平舒霖）、门冬胰岛素原料药、门冬胰岛素注射液、预混型门冬胰岛素（门冬胰岛素30注射液与门冬胰岛素50注射液）（注册商标：锐舒霖）、利拉鲁肽注射液（注册商标：统博力）、恩格列净片（注册商标：唐捷恩）、镇脑宁胶囊、糖尿病。公司被国家认定为高新技术企业、国家技术创新示范企业。","listedPrice":6.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"通化东宝,600867,通化东宝股票,通化东宝股票老虎,通化东宝股票老虎国际,通化东宝行情,通化东宝股票行情,通化东宝股价,通化东宝股市,通化东宝股票价格,通化东宝股票交易,通化东宝股票购买,通化东宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}